title: Primary central nervous system (CNS) lymphoma in immunocompetent patients.
abstract: Primary CNS lymphoma (PCNSL) has been increasing in incidence among both immunocompetent and immunocompromised patients. Today there is no uniform approach to the treatment of this disease. Whole brain irradiation (WBI) has been standard treatment, resulting in complete remission in the majority of patients, but with most patients relapsing and dying of their disease within 2 years after treatment. The addition of chemotherapy to WBI appears to prolong survival for patients younger than 60 years with median survival reaching a plateau at approximately 40 months. The issue of the best treatment for older patients remains controversial. Prospective studies will be needed, as it is impossible to draw conclusions from the nonrandomized small series published so far. This is because the prognostic variables of age and performance status to date have affected outcome more than therapy. In this review, some of the questions regarding the management of PCNSL are addressed. Since the role of radiotherapy remains unclear, we designed a new randomized multicenter study (G-PCNSL-SG-1 trial) to investigate the optimal timing of WBI after high-dose methotrexate (HD-MTX) chemotherapy.
authors.affiliation: Department of Radiation-Oncology, University Hospital of Tübingen, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany. ludwig.plasswilm@med.uni-tuebingen.de
authors.forename: L
authors.initials: L
authors.lastname: Plasswilm
authors.forename: U
authors.initials: U
authors.lastname: Herrlinger
authors.forename: A
authors.initials: A
authors.lastname: Korfel
authors.forename: M
authors.initials: M
authors.lastname: Weller
authors.forename: W
authors.initials: W
authors.lastname: Küker
authors.forename: L
authors.initials: L
authors.lastname: Kanz
authors.forename: E
authors.initials: E
authors.lastname: Thiel
authors.forename: M
authors.initials: M
authors.lastname: Bamberg
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000276:immunology* / Q000628:therapy; D003131:Combined Modality Therapy; D006801:Humans; D007121:Immunocompetence / Q000276:immunology*; D008223:Lymphoma / Q000276:immunology* / Q000628:therapy